SCHEMBL15769441

SCHEMBL15769441

CN(c1ccnc(Nc2cccc(C#N)c2)n1)[C@H]1CCCN2CCCC[C@H]12

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 5/20 0.50
SMG1 Q96Q15 1/20 0.43
CDK4 P11802 2/20 0.43
CDK2 P24941 2/20 0.43
LCK P06239 4/20 0.42
IKBKB O14920 1/20 0.42
CHUK O15111 1/20 0.42
CDC7 O00311 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
SYK P43405 3/20 0.41
PRKDC P78527 1/20 0.40
MAOB P27338 1/20 0.39
GRM5 P41594 1/20 0.39
CDK1 P06493 1/20 0.39
EPHB4 P54760 1/20 0.39
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15769494 0.85 JAK3 (0.44) JAK3CDK4CDK2LCKGSK3B
SCHEMBL15769429 0.85 JAK3 (0.45) JAK3CDK4CDK2LCKPRKDC
SCHEMBL15769702 0.84 JAK3 (0.42) JAK3SMG1CDK4CDK2LCK
SCHEMBL15769281 0.83 SYK (0.51) SMG1CDK4CDK2CDC7GSK3B
SCHEMBL15769449 0.83 SYK (0.42) JAK3SMG1CDK4CDK2IKBKB
SCHEMBL15770162 0.83 SYK (0.42) SMG1IKBKBCHUKCDC7SYK
SCHEMBL15770252 0.82 ABCG2 (0.43) CDK4CDK2CDC7SYKPRKDC
SCHEMBL15769385 0.82 JAK3 (0.47) JAK3CDC7SYKPRKDCMAOB
SCHEMBL15769445 0.77 JAK3 (0.38) JAK3LCK
SCHEMBL15769442 0.76 EPHB4 (0.44) SMG1CDK4CDK2IKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP claimed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US claimed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US claimed
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP disclosed
US-9913843-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-03-13 US disclosed
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2015-10-29 US disclosed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB JAK3 572/4885SMG1 668/4885CDK4 914/4885
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB JAK3 572/4885SMG1 668/4885CDK4 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.